About Baxalta (NYSE:BXLT)
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity14.28%
Return on Assets4.62%
Baxalta (NYSE:BXLT) Frequently Asked Questions
What is Baxalta's stock symbol?
Baxalta trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXLT."
How were Baxalta's earnings last quarter?
Baxalta Inc (NYSE:BXLT) issued its quarterly earnings data on Thursday, April, 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.01. The biotechnology company had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.47 billion. Baxalta had a return on equity of 14.28% and a net margin of 9.37%. The business's revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $0.40 EPS. View Baxalta's Earnings History.
Has Baxalta been receiving favorable news coverage?
News headlines about BXLT stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Baxalta earned a media sentiment score of 0.04 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Baxalta?
Shares of BXLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Baxalta's stock price today?
One share of BXLT stock can currently be purchased for approximately $46.02.
How can I contact Baxalta?
Baxalta's mailing address is 1200 Lakeside Dr, BANNOCKBURN, IL 60015-1243, United States. The biotechnology company can be reached via phone at +1-224-9402000.
MarketBeat Community Rating for Baxalta (BXLT)MarketBeat's community ratings are surveys of what our community members think about Baxalta and other stocks. Vote "Outperform" if you believe BXLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BXLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Baxalta (NYSE:BXLT) Dividend Information
Baxalta pays an annual dividend of $0.28 per share, with a dividend yield of 0.61%. BXLT's most recent quarterly dividend payment was Friday, July 1.
|Most Recent Dividend:||7/1/2016|
|Dividend Growth:||0.00% (3 Year Average)|
|Track Record:||2 Years of Consecutive Dividend Growth|
Baxalta (NYSE:BXLT) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Baxalta (NYSE:BXLT) SEC Filings
This page is loading this company's SEC Filings. Please wait...